Health hazard evaluation report: GHE-80-169-1300, Mylan Pharmaceuticals, Morgantown, West Virginia.
Authors
Hanke WE; Patnode R
Source
Morgantown, WV: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, National Institute for Occupational Safety and Health, GHE 80-169-1300, 1983 Apr; :1-27
In response to a request from the Oil, Chemical and Atomic Workers International Union, an evaluation was made of working conditions at the Mylan Pharmaceutical Company (SIC-2833), Morgantown, West Virginia. The company employees 225 persons in the manufacturing of specialty generic prescription drugs. Employees were concerned about asthma like respiratory symptoms, skin rashes, excessive urination, dizziness, drowsiness and depression. Possible exposures to penicillin (1406059) dust were evaluated. Production workers who had direct contact with the powdered material experienced airborne dust exposures ranging from 2.48 to 12.47 milligrams per cubic meter (mg/m3). Exposure for nonproduction workers averaged 0.12 to prevalence of attacks of shortness of breath with wheezing. A dose/response relationship was not found between the asthma/like symptoms and exposure to penicillin dust. No significant differences among the exposure groups was noted on pulmonary function testing; this may be explained partly by the use of bronchodilators during the work shift. A higher prevalence of dry, cracked skin was noted in the penicillin group than in the nonpenicillin group. The authors recommend that dust control measures be added to those already in place at the facility. Respirators should be worn by those involved in manual scooping of powders. Workers should undergo medical evaluations including a preplacement evaluation, annual checkups, and shift spirometry. Workers with decrements showing on the pulmonary function tests should be transferred to another division where dust exposure does not occur.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.